APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Plasma Protein Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Recombinant Plasma Protein Therapeutics Industry Growth and Trends Forecast to 2032

20 December 202591 pages

Choose your research edition.

Industry ResearchRecombinant Plasma Protein Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Plasma Protein Therapeutics Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Recombinant Plasma Protein Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Plasma Protein Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Plasma Protein Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Recombinant Plasma Protein Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Plasma Protein Therapeutics include Takeda, Novo Nordisk A/S, Pfizer, Pharming Group, Octapharma, CSL Limited, Bioverativ Therapeutics and Aptevo Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Recombinant Plasma Protein Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Recombinant Plasma Protein Therapeutics market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Recombinant Plasma Protein Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Recombinant Plasma Protein Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Recombinant Plasma Protein Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Recombinant Plasma Protein Therapeutics Market by Company

Takeda

Novo Nordisk A/S

Pfizer

Pharming Group

Octapharma

CSL Limited

Bioverativ Therapeutics

Aptevo Therapeutics

Recombinant Plasma Protein Therapeutics Segment by Type

Recombinant Coagulation Factors

Human C1 Esterase Inhibitor

Recombinant Plasma Protein Therapeutics Segment by Application

Von Willebrand Disease

Hemophilia A

Hemophilia B

Recombinant Plasma Protein Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Plasma Protein Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Plasma Protein Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Plasma Protein Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Plasma Protein Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Recombinant Plasma Protein Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Recombinant Coagulation Factors Table 2. Major Company of Human C1 Esterase Inhibitor Table 3. Global Recombinant Plasma Protein Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (k units) Table 5. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type (2021-2026) Table 6. Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 7. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type (2021-2026) Table 8. Global Recombinant Plasma Protein Therapeutics Price by Type (2021-2026) & (US$/unit) Table 9. Global Recombinant Plasma Protein Therapeutics Sales by Type (2027-2032) & (k units) Table 10. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type (2027-2032) Table 11. Global Recombinant Plasma Protein Therapeutics Sales by Type (2027-2032) & (US$ Million) Table 12. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type (2027-2032) Table 13. Global Recombinant Plasma Protein Therapeutics Price by Type (2027-2032) & (US$/unit) Table 14. North America Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (k units) Table 15. North America Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (k units) Table 17. Europe Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (k units) Table 21. Latin America Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 24. Recombinant Plasma Protein Therapeutics Industry Trends Table 25. Recombinant Plasma Protein Therapeutics Industry Drivers Table 26. Recombinant Plasma Protein Therapeutics Industry Opportunities and Challenges Table 27. Recombinant Plasma Protein Therapeutics Industry Restraints Table 28. Global Recombinant Plasma Protein Therapeutics Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Company (2021-2026) Table 30. Global Recombinant Plasma Protein Therapeutics Sales by Company (2021-2026) & (k units) Table 31. Global Recombinant Plasma Protein Therapeutics Sales Share by Company (2021-2026) Table 32. Global Recombinant Plasma Protein Therapeutics Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Recombinant Plasma Protein Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Recombinant Plasma Protein Therapeutics Major Company Production Sites and Headquarters Table 35. Global Recombinant Plasma Protein Therapeutics Company, Product Type & Application Table 36. Global Recombinant Plasma Protein Therapeutics Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Recombinant Plasma Protein Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Recombinant Plasma Protein Therapeutics Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Recombinant Plasma Protein Therapeutics Sales by Region (2021-2026) & (k units) Table 41. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Region (2021-2026) Table 42. Global Recombinant Plasma Protein Therapeutics Sales by Region (2021-2026) & (US$ Million) Table 43. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Region (2021-2026) Table 44. Global Recombinant Plasma Protein Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Recombinant Plasma Protein Therapeutics Sales by Region (2027-2032) & (k units) Table 46. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Region (2027-2032) Table 47. Global Recombinant Plasma Protein Therapeutics Sales by Region (2027-2032) & (US$ Million) Table 48. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Region (2027-2032) Table 49. Global Recombinant Plasma Protein Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Recombinant Plasma Protein Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (k units) Table 52. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application (2021-2026) Table 53. Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 54. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application (2021-2026) Table 55. Global Recombinant Plasma Protein Therapeutics Price by Application (2021-2026) & (US$/unit) Table 56. Global Recombinant Plasma Protein Therapeutics Sales by Application (2027-2032) & (k units) Table 57. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application (2027-2032) Table 58. Global Recombinant Plasma Protein Therapeutics Sales by Application (2027-2032) & (US$ Million) Table 59. Global Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application (2027-2032) Table 60. Global Recombinant Plasma Protein Therapeutics Price by Application (2027-2032) & (US$/unit) Table 61. North America Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (k units) Table 62. North America Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (k units) Table 64. Europe Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (k units) Table 68. Latin America Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 71. Takeda Company Information Table 72. Takeda Business Overview Table 73. Takeda Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Takeda Recombinant Plasma Protein Therapeutics Product Portfolio Table 75. Takeda Recent Development Table 76. Novo Nordisk A/S Company Information Table 77. Novo Nordisk A/S Business Overview Table 78. Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Portfolio Table 80. Novo Nordisk A/S Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Pfizer Recombinant Plasma Protein Therapeutics Product Portfolio Table 85. Pfizer Recent Development Table 86. Pharming Group Company Information Table 87. Pharming Group Business Overview Table 88. Pharming Group Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Pharming Group Recombinant Plasma Protein Therapeutics Product Portfolio Table 90. Pharming Group Recent Development Table 91. Octapharma Company Information Table 92. Octapharma Business Overview Table 93. Octapharma Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Octapharma Recombinant Plasma Protein Therapeutics Product Portfolio Table 95. Octapharma Recent Development Table 96. CSL Limited Company Information Table 97. CSL Limited Business Overview Table 98. CSL Limited Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. CSL Limited Recombinant Plasma Protein Therapeutics Product Portfolio Table 100. CSL Limited Recent Development Table 101. Bioverativ Therapeutics Company Information Table 102. Bioverativ Therapeutics Business Overview Table 103. Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio Table 105. Bioverativ Therapeutics Recent Development Table 106. Aptevo Therapeutics Company Information Table 107. Aptevo Therapeutics Business Overview Table 108. Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio Table 110. Aptevo Therapeutics Recent Development Table 111. North America Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 112. North America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (k units) Table 113. North America Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2021-2026) Table 114. North America Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 115. North America Recombinant Plasma Protein Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 116. North America Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. North America Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 118. North America Recombinant Plasma Protein Therapeutics Market Share by Country (2021-2026) Table 119. North America Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. North America Recombinant Plasma Protein Therapeutics Market Share Forecast by Country (2027-2032) Table 121. Europe Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 122. Europe Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (k units) Table 123. Europe Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2021-2026) Table 124. Europe Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 125. Europe Recombinant Plasma Protein Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 126. Europe Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Europe Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 128. Europe Recombinant Plasma Protein Therapeutics Market Share by Country (2021-2026) Table 129. Europe Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Europe Recombinant Plasma Protein Therapeutics Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (k units) Table 133. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2021-2026) Table 134. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 135. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 138. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share by Country (2021-2026) Table 139. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share Forecast by Country (2027-2032) Table 141. Latin America Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. Latin America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (k units) Table 143. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2021-2026) Table 144. Latin America Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 145. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 146. Latin America Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Latin America Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 148. Latin America Recombinant Plasma Protein Therapeutics Market Share by Country (2021-2026) Table 149. Latin America Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Latin America Recombinant Plasma Protein Therapeutics Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026) & (k units) Table 153. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share by Country (2021-2026) Table 154. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 155. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 158. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Share by Country (2021-2026) Table 159. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Share Forecast by Country (2027-2032) Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Recombinant Plasma Protein Therapeutics Distributors List Table 164. Recombinant Plasma Protein Therapeutics Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Recombinant Plasma Protein Therapeutics Image Figure 2. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Plasma Protein Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Plasma Protein Therapeutics Sales (2021-2032) & (k units) Figure 5. Recombinant Coagulation Factors Image Figure 6. Global Recombinant Coagulation Factors Sales YoY Growth (2021-2032) & (k units) Figure 7. Human C1 Esterase Inhibitor Image Figure 8. Global Human C1 Esterase Inhibitor Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Recombinant Plasma Protein Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Recombinant Plasma Protein Therapeutics Market Share by Type 2025 VS 2032 Figure 11. North America Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type in 2025 Figure 12. North America Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type in 2025 Figure 13. Europe Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type in 2025 Figure 14. Europe Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type in 2025 Figure 17. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Recombinant Plasma Protein Therapeutics Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Von Willebrand Disease Image Figure 24. Global Von Willebrand Disease Sales YoY Growth (2021-2032) & (k units) Figure 25. Hemophilia A Image Figure 26. Global Hemophilia A Sales YoY Growth (2021-2032) & (k units) Figure 27. Hemophilia B Image Figure 28. Global Hemophilia B Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Recombinant Plasma Protein Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Recombinant Plasma Protein Therapeutics Market Share by Application 2025 VS 2032 Figure 31. North America Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application in 2025 Figure 32. North America Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application in 2025 Figure 33. Europe Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application in 2025 Figure 34. Europe Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application in 2025 Figure 37. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Market Share in Value by Application in 2025 Figure 41. North America Recombinant Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Recombinant Plasma Protein Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Recombinant Plasma Protein Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Recombinant Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Recombinant Plasma Protein Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Recombinant Plasma Protein Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Recombinant Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Recombinant Plasma Protein Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Recombinant Plasma Protein Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Recombinant Plasma Protein Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Recombinant Plasma Protein Therapeutics Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Recombinant Plasma Protein Therapeutics Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Coagulation Factors
  • Human C1 Esterase Inhibitor
Applications
  • Von Willebrand Disease
  • Hemophilia A
  • Hemophilia B
Companies covered
  • Takeda
  • Novo Nordisk A/S
  • Pfizer
  • Pharming Group
  • Octapharma
  • CSL Limited
  • Bioverativ Therapeutics
  • Aptevo Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Plasma Protein Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Recombinant Plasma Protein Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Recombinant Plasma Protein Therapeutics Market by Type
  6. 1.3.1 Recombinant Coagulation Factors
  7. 1.3.2 Human C1 Esterase Inhibitor
  8. 1.4 Global Recombinant Plasma Protein Therapeutics Market Size by Type
  9. 1.4.1 Global Recombinant Plasma Protein Therapeutics Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Recombinant Plasma Protein Therapeutics Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Recombinant Plasma Protein Therapeutics Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Recombinant Plasma Protein Therapeutics Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Recombinant Plasma Protein Therapeutics Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Recombinant Plasma Protein Therapeutics Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Recombinant Plasma Protein Therapeutics Industry Trends
  2. 2.2 Recombinant Plasma Protein Therapeutics Industry Drivers
  3. 2.3 Recombinant Plasma Protein Therapeutics Industry Opportunities and Challenges
  4. 2.4 Recombinant Plasma Protein Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Recombinant Plasma Protein Therapeutics Revenue (2021-2026)
  2. 3.2 Global Top Players by Recombinant Plasma Protein Therapeutics Sales (2021-2026)
  3. 3.3 Global Top Players by Recombinant Plasma Protein Therapeutics Price (2021-2026)
  4. 3.4 Global Recombinant Plasma Protein Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Plasma Protein Therapeutics Major Company Production Sites & Headquarters
  6. 3.6 Global Recombinant Plasma Protein Therapeutics Company, Product Type & Application
  7. 3.7 Global Recombinant Plasma Protein Therapeutics Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Plasma Protein Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Plasma Protein Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Plasma Protein Therapeutics Tier 1, Tier 2, and Tier 3
4 Recombinant Plasma Protein Therapeutics Regional Status and Outlook
  1. 4.1 Global Recombinant Plasma Protein Therapeutics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Recombinant Plasma Protein Therapeutics Historic Market Size by Region
  3. 4.2.1 Global Recombinant Plasma Protein Therapeutics Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Recombinant Plasma Protein Therapeutics Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Recombinant Plasma Protein Therapeutics Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Recombinant Plasma Protein Therapeutics Forecasted Market Size by Region
  7. 4.3.1 Global Recombinant Plasma Protein Therapeutics Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Recombinant Plasma Protein Therapeutics Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Recombinant Plasma Protein Therapeutics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Recombinant Plasma Protein Therapeutics by Application
  1. 5.1 Recombinant Plasma Protein Therapeutics Market by Application
  2. 5.1.1 Von Willebrand Disease
  3. 5.1.2 Hemophilia A
  4. 5.1.3 Hemophilia B
  5. 5.2 Global Recombinant Plasma Protein Therapeutics Market Size by Application
  6. 5.2.1 Global Recombinant Plasma Protein Therapeutics Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Recombinant Plasma Protein Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Recombinant Plasma Protein Therapeutics Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Recombinant Plasma Protein Therapeutics Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Recombinant Plasma Protein Therapeutics Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Recombinant Plasma Protein Therapeutics Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Recombinant Plasma Protein Therapeutics Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Novo Nordisk A/S
  8. 6.2.1 Novo Nordisk A/S Company Information
  9. 6.2.2 Novo Nordisk A/S Business Overview
  10. 6.2.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Portfolio
  12. 6.2.5 Novo Nordisk A/S Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Recombinant Plasma Protein Therapeutics Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Pharming Group
  20. 6.4.1 Pharming Group Company Information
  21. 6.4.2 Pharming Group Business Overview
  22. 6.4.3 Pharming Group Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Pharming Group Recombinant Plasma Protein Therapeutics Product Portfolio
  24. 6.4.5 Pharming Group Recent Developments
  25. 6.5 Octapharma
  26. 6.5.1 Octapharma Company Information
  27. 6.5.2 Octapharma Business Overview
  28. 6.5.3 Octapharma Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Octapharma Recombinant Plasma Protein Therapeutics Product Portfolio
  30. 6.5.5 Octapharma Recent Developments
  31. 6.6 CSL Limited
  32. 6.6.1 CSL Limited Company Information
  33. 6.6.2 CSL Limited Business Overview
  34. 6.6.3 CSL Limited Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 CSL Limited Recombinant Plasma Protein Therapeutics Product Portfolio
  36. 6.6.5 CSL Limited Recent Developments
  37. 6.7 Bioverativ Therapeutics
  38. 6.7.1 Bioverativ Therapeutics Company Information
  39. 6.7.2 Bioverativ Therapeutics Business Overview
  40. 6.7.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
  42. 6.7.5 Bioverativ Therapeutics Recent Developments
  43. 6.8 Aptevo Therapeutics
  44. 6.8.1 Aptevo Therapeutics Company Information
  45. 6.8.2 Aptevo Therapeutics Business Overview
  46. 6.8.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
  48. 6.8.5 Aptevo Therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America Recombinant Plasma Protein Therapeutics Sales by Country
  2. 7.1.1 North America Recombinant Plasma Protein Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026)
  4. 7.1.3 North America Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032)
  5. 7.2 North America Recombinant Plasma Protein Therapeutics Market Size by Country
  6. 7.2.1 North America Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026)
  8. 7.2.3 North America Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Recombinant Plasma Protein Therapeutics Sales by Country
  2. 8.1.1 Europe Recombinant Plasma Protein Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026)
  4. 8.1.3 Europe Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Recombinant Plasma Protein Therapeutics Market Size by Country
  6. 8.2.1 Europe Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026)
  8. 8.2.3 Europe Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Country
  2. 9.1.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size by Country
  6. 9.2.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Recombinant Plasma Protein Therapeutics Sales by Country
  2. 10.1.1 South America Recombinant Plasma Protein Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026)
  4. 10.1.3 South America Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032)
  5. 10.2 South America Recombinant Plasma Protein Therapeutics Market Size by Country
  6. 10.2.1 South America Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026)
  8. 10.2.3 South America Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country
  2. 11.1.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country
  6. 11.2.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Recombinant Plasma Protein Therapeutics Value Chain Analysis
  2. 12.1.1 Recombinant Plasma Protein Therapeutics Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Recombinant Plasma Protein Therapeutics Production Mode & Process
  7. 12.2 Recombinant Plasma Protein Therapeutics Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Recombinant Plasma Protein Therapeutics Distributors
  10. 12.2.3 Recombinant Plasma Protein Therapeutics Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst